Travere Therapeutics/$TVTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- Ticker
- $TVTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 497
- Headquarters
- San Diego, United States
- Website
- www.travere.com
TVTX Metrics
BasicAdvanced
$4.7B
-
-$1.31
1.12
-
Price and volume
Market cap
$4.7B
Beta
1.12
52-week high
$68.73
52-week low
$22.59
Average daily volume
2.2M
Financial strength
Current ratio
3.003
Quick ratio
2.747
Long term debt to equity
27.003
Total debt to equity
27.283
Interest coverage (TTM)
-2.30%
Profitability
EBITDA (TTM)
32.403
Gross margin (TTM)
61.07%
Net profit margin (TTM)
-18.66%
Operating margin (TTM)
-3.13%
Effective tax rate (TTM)
3.32%
Revenue per employee (TTM)
$1,310,000
Management effectiveness
Return on assets (TTM)
-1.84%
Return on equity (TTM)
-321.22%
Valuation
Price to revenue (TTM)
7.026
Price to book
209.32
Price to tangible book (TTM)
-33.4
Price to free cash flow (TTM)
-167
Free cash flow yield (TTM)
-0.60%
Free cash flow per share (TTM)
-0.296
Growth
Revenue change (TTM)
49.38%
Earnings per share change (TTM)
29.28%
3-year revenue growth (CAGR)
71.30%
10-year revenue growth (CAGR)
17.78%
3-year earnings per share growth (CAGR)
2.39%
10-year earnings per share growth (CAGR)
1.41%
What the Analysts think about TVTX
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
Analyst projections of the future price of Travere Therapeutics stock.
Bulls say / Bears say
FILSPARI is delivering rapid commercial growth: third-quarter US sales rose 120% year on year to $200.2 million, with 1,932 new patient start forms across IgAN and FSGS. That gives Travere a growing marketed revenue base. (Travere Therapeutics)
The FDA’s April approval of FILSPARI for FSGS gives Travere the first and only approved medicine for the eligible FSGS population, opening a second commercial indication alongside IgAN. (Travere Therapeutics)
Pegtibatinase offers a potential longer-term growth driver beyond FILSPARI: its Phase 3 HARMONY trial is enrolling, with results expected in the second half of 2027. Travere says it could become the first disease-modifying treatment for classical HCU. (Travere Therapeutics)
The FDA said Travere’s FILSPARI promotional visual aid made misleading claims about kidney preservation and understated safety risks, including the drug’s boxed warnings for liver injury and harm to an unborn child. This could complicate promotion and reinforces important treatment risks. (MM+M)
Underlying demand may be less strong than headline sales suggest: new patient start forms fell 4% sequentially to 1,932, and about $8 million of Q3 sales came from unusually high pharmacy inventory that management expects to unwind in Q4. (Investing.com)
Profitability remains uncertain: Travere reported a $52.3 million Q3 net loss, while higher research and commercial spending weighed on results. The quarter also included a $113.1 million one-off licensing-related research charge, making earnings volatile. (Travere Therapeutics, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
TVTX Financial Performance
Revenues and expenses
TVTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
TVTX News
AllArticlesVideos
Funds containing TVTX
Fund name | Fund size | $TVTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.30% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.30% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.15% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.15% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.